^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Carteyva (relmacabtagene autoleucel)

    i
    Other names: CD19 CAR T cells, relma-cel, JWCAR029, JWCAR 029, JWCAR-029, autologous CD19-targeted chimeric antigen receptor T cells
    Company:
    JW (Cayman) Therap
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    13d
    Glofitamab Combined With CAR-T Therapy in R/R DLBCL (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Carteyva (relmacabtagene autoleucel) • Columvi (glofitamab-gxbm)
    4ms
    Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Zhengzhou University
    New trial
    |
    Tyvyt (sintilimab) • Inokai (orelabrutinib) • Carteyva (relmacabtagene autoleucel)
    4ms
    Clinical outcome and immunophenotype of axicabtagene ciloleucel (axi-cel) and relmacabtagene autoleucel (relma-cel) in relapsed/refractory large B-Cell lymphoma on Chinese population: a single-center experience. (PubMed, Ann Hematol)
    In this cohort, CAR-T therapies for r/r large B-cell lymphoma yielded high response rates and promising survival outcomes, with axi-cel showing superior efficacy but higher CRS incidence compared to relma-cel. The study highlights the need for optimal stem-like memory T-cell proportions in CAR-T products for improved efficacy. Prospective multicenter studies are warranted to confirm these findings in larger patient populations.
    Clinical data • Journal • IO biomarker
    |
    CCR7 (Chemokine (C-C motif) receptor 7)
    |
    Yescarta (axicabtagene ciloleucel) • Carteyva (relmacabtagene autoleucel)
    6ms
    Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Tyvyt (sintilimab) • cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)
    10ms
    Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • Carteyva (relmacabtagene autoleucel)
    11ms
    Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Shanghai Ming Ju Biotechnology Co., Ltd. | Not yet recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> Nov 2029
    Enrollment closed • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)
    over1year
    CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations. (PubMed, Cytotherapy)
    Our study suggests that r/r DLBCL patients with both DE status and TP53 alterations treated with CAR-T therapy are more likely to have a poorer clinical prognosis. However, CAR-T therapy has the potential to improve the prognosis of patients with only TP53 alterations or DE status to be similar to that of patients without these abnormalities.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Carteyva (relmacabtagene autoleucel)
    over1year
    CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, Shanghai Ming Ju Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Oct 2024
    Enrollment closed • Trial primary completion date • CAR T-Cell Therapy
    |
    Carteyva (relmacabtagene autoleucel)
    over1year
    JWCAR029-117: CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=12, Recruiting, Shanghai Ming Ju Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    Carteyva (relmacabtagene autoleucel)
    over1year
    CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors (clinicaltrials.gov)
    P2, N=16, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Carteyva (relmacabtagene autoleucel)
    over1year
    CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, Shanghai Ming Ju Biotechnology Co., Ltd.
    New P2 trial • CAR T-Cell Therapy
    |
    Carteyva (relmacabtagene autoleucel)
    over1year
    Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis (clinicaltrials.gov)
    P1, N=6, Recruiting, Liangjing Lu | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Carteyva (relmacabtagene autoleucel)